Division of Cesca Therapeutics Inc.
Latest From TotipotentRx Corp.
The agency noted deficiencies in Cesca Therapeutcs' investigational device exemption submission for the CLIRST III pivotal study of its SurgWerks stem cell therapy system in critical limb ischemia. But the company says the overall message for the 224-patient study is positive.
Derived from Strategic Transactions, Elsevier Business Intelligence’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing.
- Gene Therapy, Cell Therapy
- Contract Research, Toxicology Testing-CRO
- Therapeutic Areas
- North America
- Parent & Subsidiaries
- Cesca Therapeutics Inc.
- Senior Management
Kenneth L Harris, Chmn. & CEO
Venkatesh Ponemone, PhD, Dir., Clin. & Scientific Affairs
- Contact Info
Phone: (213) 221-7373
548 S. Spring St.
Los Angeles, CA 90013
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.